Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q9UBY8
UPID:
CLN8_HUMAN
Alternative names:
-
Alternative UPACC:
Q9UBY8; Q86U71; Q96I95
Background:
Protein CLN8, encoded by the gene with accession number Q9UBY8, is implicated in neuronal differentiation and survival. It is believed to play a crucial role in cell proliferation during neuronal differentiation and in protection against cell death, highlighting its significance in neural development and function.
Therapeutic significance:
Protein CLN8 is directly associated with neuronal ceroid lipofuscinosis type 8 and its Northern epilepsy variant, both of which are progressive neurodegenerative disorders. Understanding the role of Protein CLN8 could open doors to potential therapeutic strategies for these debilitating conditions.